Document is current

Article History

Received: 4 September 2025

Accepted: 20 October 2025

First Online: 6 November 2025

Declarations

:

: KIE has consulted for MedRhythms, Inc. and NeoAuvra, Inc. TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers, Neurogen Biomarking LLC. and Alzheon (which may come with minority stock equity interest/stock options), outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer’s Association and Neurogen Biomarking LLC., outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific tau antibodies and assays to third party organizations. He has received honoraria for speaker/grant review engagements from the NIH, UPENN, UW‐Madison, the Cherry Blossom symposium, the HABS-HD/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona‐Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. TKK serves/has served as a guest editor for npj Dementia, as an invited member of the World Health Organization committee to develop preferred product characteristics for blood-based biomarker diagnostics for Alzheimer’s disease, as an executive committee member for the Human Amyloid Imaging (HAI) conference, as an elected member of the NACC ADRCs Steering Committee, as co-director of the NACC ADRCs Biofluid Biomarker Working Group, and as a member of the Alzheimer’s Association committees to develop Appropriate Use Criteria for clinical use of blood-based biomarkers, and treatment related amyloid clearance. TKK is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents/compositions, that may generate income for the institution and/or self should they be licensed and/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; 63/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer’s Disease Patients; 63/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer's Disease; 63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702–2: Detection of oligomeric tau and soluble tau aggregates. The rest of the authors have nothing to declare.